Recent Updates
Recently added Catalysts
RADX Neutral Sentiment Score: 50/100

Notification of Release of Shares from Escrow

Thursday, November 16, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has announced the release of shares from escrow, which is a significant corporate update. This notification is part of ongoing announcements related to the company's clinical studies and capital raising efforts. The company has been active in clinical trials, including a recent Phase 1/2a study of BetaBart (RV-01).

Market Sentiment Analysis

Full Press Release Details

• Announcements
• November 16, 2023
Loading Viewer…

More Announcements & Updates

• Updates
• September 4, 2024
• Announcements
• December 10, 2024
• Announcements
• February 28, 2023
• Announcements
• July 5, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research
Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics escrow clinical trials BetaBart
Last updated: Nov 16, 2023